5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.
Ellingrod
Vicki L
VL
Perry
Paul J
PJ
Lund
Brian C
BC
Bever-Stille
Kristy
K
Fleming
Frank
F
Holman
Timothy L
TL
Miller
Del
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000097:blood / Q000627:therapeutic use*; D001569:Benzodiazepines; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D011110:Polymorphism, Genetic / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin / Q000235:genetics* / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine